$2.83 Billion is the total value of Boxer Capital, LLC's 95 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 18.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | Mirati Therapeutics Inc. | $323,060,000 | -5.7% | 2,000,000 | 0.0% | 11.40% | -1.9% | |
| BGNE | BeiGene Ltdsponsored adr | $262,262,000 | -1.4% | 764,188 | 0.0% | 9.25% | +2.6% | |
| SWTX | Springworks Therapeutics Inc. | $171,075,000 | +12.0% | 2,075,905 | 0.0% | 6.04% | +16.5% | |
| ITOS | iTeos Therapeutics Inc. | $111,450,000 | -25.0% | 4,345,016 | 0.0% | 3.93% | -21.9% | |
| RVMD | Revolution Medicines Inc. | $110,591,000 | -30.8% | 3,484,264 | 0.0% | 3.90% | -28.0% | |
| PMVP | PMV Pharmaceuticals Inc. | $77,483,000 | +3.9% | 2,268,236 | 0.0% | 2.73% | +8.1% | |
| RCKT | Rocket Pharmaceuticals Inc. | $64,931,000 | -0.2% | 1,466,051 | 0.0% | 2.29% | +3.9% | |
| SGEN | Seagen Inc. | $63,152,000 | +13.7% | 400,000 | 0.0% | 2.23% | +18.3% | |
| SAGE | Sage Therapeutics Inc. | $62,150,000 | -24.1% | 1,094,000 | 0.0% | 2.19% | -21.0% | |
| RCUS | Arcus Biosciences Inc. | $57,251,000 | -2.2% | 2,084,883 | 0.0% | 2.02% | +1.8% | |
| SBTX | Silverback Therapeutics Inc. | $51,752,000 | -29.2% | 1,675,377 | 0.0% | 1.83% | -26.3% | |
| ARGX | ArgenX SEsponsored adr | $51,461,000 | +9.3% | 170,926 | 0.0% | 1.82% | +13.8% | |
| RLAY | Relay Therapeutics Inc. | $47,352,000 | +5.8% | 1,294,132 | 0.0% | 1.67% | +10.2% | |
| IDYA | Ideaya Biosciences Inc. | $46,237,000 | -10.7% | 2,202,812 | 0.0% | 1.63% | -7.1% | |
| Marinus Pharmaceuticals Inc. | $43,056,000 | +15.9% | 2,400,000 | 0.0% | 1.52% | +20.6% | ||
| CYTK | Cytokinetics Inc. | $41,559,000 | -14.9% | 2,100,000 | 0.0% | 1.47% | -11.5% | |
| DBVT | DBV Technologies SAsponsored adr | $41,214,000 | +2.6% | 7,534,598 | 0.0% | 1.45% | +6.8% | |
| CNTB | Connect Biopharma Holdings Ltd.ads | $40,648,000 | +5.6% | 2,081,323 | 0.0% | 1.43% | +9.8% | |
| NUVB | Nuvation Bio Inc. | $40,415,000 | -10.9% | 4,341,009 | 0.0% | 1.43% | -7.3% | |
| MRUS | Merus NV | $40,033,000 | +0.9% | 1,900,000 | 0.0% | 1.41% | +4.9% | |
| SNDX | Syndax Pharmaceuticals Inc. | $39,281,000 | -23.2% | 2,287,782 | 0.0% | 1.39% | -20.1% | |
| ANAB | Anaptys Bio Inc. | $33,709,000 | +20.3% | 1,300,000 | 0.0% | 1.19% | +25.2% | |
| BMEA | New | Biomea Fusion Inc. | $32,600,000 | – | 2,088,405 | +100.0% | 1.15% | – |
| NRIX | Nurix Therapeutics Inc. | $32,496,000 | -14.7% | 1,224,892 | 0.0% | 1.15% | -11.2% | |
| ALGS | Aligos Therapeutics Inc. | $31,108,000 | -10.4% | 1,526,048 | 0.0% | 1.10% | -6.7% | |
| BCAB | BioAtla Inc. | $29,087,000 | -16.6% | 686,347 | 0.0% | 1.03% | -13.3% | |
| RNA | Avidity Biosciences Inc. | $27,708,000 | +13.3% | 1,121,327 | 0.0% | 0.98% | +18.0% | |
| CGEM | Cullinan Oncology Inc. | $27,658,000 | -38.2% | 1,074,082 | 0.0% | 0.98% | -35.7% | |
| DAWN | New | Day One Biopharmaceuticals Inc. | $27,095,000 | – | 1,189,943 | +100.0% | 0.96% | – |
| AMRN | Amarin Corp PLCspons adr new | $26,280,000 | -29.5% | 6,000,000 | 0.0% | 0.93% | -26.7% | |
| RACA | Buy | Therapeutics Acquisition Corp | $25,675,000 | +62.9% | 2,500,000 | +66.7% | 0.91% | +69.3% |
| PASG | Passage Bio Inc. | $25,531,000 | -24.3% | 1,928,315 | 0.0% | 0.90% | -21.2% | |
| KNTE | Kinnate Biopharma Inc. | $24,815,000 | -25.3% | 1,065,939 | 0.0% | 0.88% | -22.2% | |
| BDTX | Black Diamond Therapeutics Inc. | $24,561,000 | -49.8% | 2,014,858 | 0.0% | 0.87% | -47.7% | |
| KDMN | Kadmon Holdings Inc. | $24,017,000 | -0.5% | 6,205,882 | 0.0% | 0.85% | +3.4% | |
| FOLD | Amicus Therapeutics Inc. | $22,413,000 | -2.4% | 2,325,000 | 0.0% | 0.79% | +1.5% | |
| GHRS | New | GH Research PLCordinary shares | $22,021,000 | – | 1,013,399 | +100.0% | 0.78% | – |
| AGEN | Agenus Inc. | $21,960,000 | +101.8% | 4,000,000 | 0.0% | 0.78% | +110.0% | |
| KURA | Kura Oncology Inc. | $21,899,000 | -26.2% | 1,050,289 | 0.0% | 0.77% | -23.2% | |
| BMRN | Biomarin Pharmaceutical Inc. | $20,860,000 | +10.5% | 250,000 | 0.0% | 0.74% | +15.0% | |
| GOSS | Gossamer Bio Inc. | $20,806,000 | -12.2% | 2,562,358 | 0.0% | 0.73% | -8.7% | |
| AKRO | Akero Therapeutics Inc. | $20,629,000 | -14.5% | 831,495 | 0.0% | 0.73% | -11.0% | |
| CNTA | New | Centessa Pharmaceuticals PLCsponsored ads | $20,083,000 | – | 904,227 | +100.0% | 0.71% | – |
| MREO | Mereo Biopharma Group PLCads | $19,739,000 | -5.9% | 6,226,673 | 0.0% | 0.70% | -2.2% | |
| EPIX | Essa Pharma Inc. | $19,628,000 | -1.6% | 687,000 | 0.0% | 0.69% | +2.4% | |
| ODT | Odonate Therapeutics Inc. | $19,569,000 | +2.0% | 5,607,086 | 0.0% | 0.69% | +6.2% | |
| CDAK | Codiak Biosciences Inc. | $19,087,000 | +22.9% | 1,030,065 | 0.0% | 0.67% | +27.7% | |
| BCEL | Atreca Inc. | $18,764,000 | -44.4% | 2,202,333 | 0.0% | 0.66% | -42.2% | |
| CERE | Cerevel Therapeutics Holding Inc. | $18,305,000 | +86.6% | 714,500 | 0.0% | 0.65% | +94.0% | |
| RAIN | New | Rain Therapeutics Inc. | $18,260,000 | – | 1,175,000 | +100.0% | 0.64% | – |
| ELEV | New | Elevation Oncology Inc. | $18,205,000 | – | 1,341,530 | +100.0% | 0.64% | – |
| CBAY | Cymabay Therapeutics Inc. | $17,440,000 | -4.0% | 4,000,000 | 0.0% | 0.62% | -0.2% | |
| TLIS | Talis Biomedical Corp. | $17,108,000 | -14.2% | 1,550,998 | 0.0% | 0.60% | -10.7% | |
| XENE | New | Xenon Pharmaceuticals Inc. | $15,957,000 | – | 857,000 | +100.0% | 0.56% | – |
| SLDB | Solid Biosciences Inc. | $15,499,000 | -33.8% | 4,234,574 | 0.0% | 0.55% | -31.1% | |
| ACHL | Sell | Achilles Therapeutics PLCsponsored ads | $15,038,000 | -40.9% | 1,536,016 | -0.0% | 0.53% | -38.4% |
| FSTX | New | F-Star Therapeutics Inc. | $15,045,000 | – | 1,751,428 | +100.0% | 0.53% | – |
| MIST | Milestone Pharmaceuticals Inc. | $14,147,000 | -5.0% | 2,572,194 | 0.0% | 0.50% | -1.2% | |
| NLTX | Neoleukin Therapeutics Inc. | $13,855,000 | -25.0% | 1,501,058 | 0.0% | 0.49% | -22.0% | |
| CABA | Cabaletta Bio Inc. | $13,789,000 | -22.5% | 1,603,361 | 0.0% | 0.49% | -19.5% | |
| SELB | Selecta Biosciences Inc. | $13,727,000 | -7.6% | 3,284,072 | 0.0% | 0.48% | -4.0% | |
| PSTX | Poseida Therapeutics Inc. | $12,536,000 | +4.9% | 1,251,055 | 0.0% | 0.44% | +9.1% | |
| IMVT | Immunovant Inc. | $10,570,000 | -34.1% | 1,000,000 | 0.0% | 0.37% | -31.4% | |
| ESPR | Esperion Therapeutics Inc. | $10,575,000 | -24.6% | 500,000 | 0.0% | 0.37% | -21.6% | |
| NGM | New | NGM Biopharmaceuticals Inc. | $9,860,000 | – | 500,000 | +100.0% | 0.35% | – |
| IMMP | Buy | Immutep Ltd.sponsored ads | $9,675,000 | +57.6% | 2,500,000 | +25.0% | 0.34% | +63.9% |
| BLU | Bellus Health Inc. | $9,252,000 | -19.0% | 2,975,000 | 0.0% | 0.33% | -15.8% | |
| MTNB | Matinas Biopharma Holdings Inc. | $8,895,000 | -26.2% | 11,478,634 | 0.0% | 0.31% | -23.2% | |
| GMTX | Gemini Therapeutics Inc. | $8,411,000 | -52.3% | 1,300,000 | 0.0% | 0.30% | -50.3% | |
| MEIP | MEI Pharma Inc. | $8,302,000 | -16.9% | 2,913,091 | 0.0% | 0.29% | -13.6% | |
| QURE | UniQure NV | $7,700,000 | -8.6% | 250,000 | 0.0% | 0.27% | -4.9% | |
| NAUT | New | Nautilus Biotechnology Inc. | $7,575,000 | – | 750,000 | +100.0% | 0.27% | – |
| VINC | New | VincerX Pharma Inc. | $5,846,000 | – | 450,000 | +100.0% | 0.21% | – |
| ASMB | Assembly Biosciences Inc. | $5,820,000 | -15.7% | 1,500,000 | 0.0% | 0.20% | -12.4% | |
| MIRM | Mirum Pharmaceuticals Inc. | $5,481,000 | -12.8% | 317,000 | 0.0% | 0.19% | -9.4% | |
| BLSA | BCLS Acquisition Corp | $5,265,000 | -0.4% | 500,000 | 0.0% | 0.19% | +3.9% | |
| RACB | Research Alliance Corp II | $5,070,000 | -1.1% | 500,000 | 0.0% | 0.18% | +2.9% | |
| PANA | New | Panacea Acquisition Corp II | $5,010,000 | – | 500,000 | +100.0% | 0.18% | – |
| JYAC | JIYA Acquisition Corp | $4,970,000 | +1.0% | 500,000 | 0.0% | 0.18% | +4.8% | |
| HLXA | Helix Acquisition Corp | $4,132,000 | +1.3% | 400,000 | 0.0% | 0.15% | +5.8% | |
| HSAQ | Health Sciences Acquisition Corp II | $4,080,000 | -8.8% | 400,000 | 0.0% | 0.14% | -5.3% | |
| KNSA | Kiniksa Pharmaceuticals Ltd. | $4,048,000 | -24.7% | 290,577 | 0.0% | 0.14% | -21.4% | |
| AGLE | Aeglea Biotherapeutics Inc. | $3,828,000 | -12.1% | 550,000 | 0.0% | 0.14% | -8.8% | |
| LJPC | La Jolla Pharmaceutical Co. | $3,812,000 | +0.9% | 890,700 | 0.0% | 0.13% | +4.7% | |
| New | Catabasis Pharmaceuticals Inc. | $3,745,000 | – | 1,775,000 | +100.0% | 0.13% | – | |
| ORIC | Oric Pharmaceuticals Inc. | $3,538,000 | -27.8% | 200,000 | 0.0% | 0.12% | -24.7% | |
| GNCA | Genocea Biosciences Inc. | $2,655,000 | -13.6% | 1,134,453 | 0.0% | 0.09% | -9.6% | |
| CHFWU | Consonance HFW Acquisition Corpunit 99/99/9999 | $2,042,000 | +4.6% | 200,000 | 0.0% | 0.07% | +9.1% | |
| TARA | Protara Therapeutics Inc. | $2,038,000 | -38.1% | 209,227 | 0.0% | 0.07% | -35.7% | |
| LSAQ | Lifesci Acquisition II Corp | $2,000,000 | -1.4% | 200,000 | 0.0% | 0.07% | +2.9% | |
| OMEG | Omega Alpha SPACcl a | $1,990,000 | +0.5% | 200,000 | 0.0% | 0.07% | +4.5% | |
| CLRB | Cellectar Biosciences Inc. | $1,095,000 | -26.1% | 920,000 | 0.0% | 0.04% | -22.0% | |
| BOLT | Bolt Biotherapeutics Inc. | $773,000 | -53.0% | 50,000 | 0.0% | 0.03% | -51.8% | |
| NUVBWS | Nuvation Bio Inc.w exp 07/07/202 | $693,000 | -2.7% | 266,666 | 0.0% | 0.02% | 0.0% | |
| ZGNX | Zogenix Inc. | $472,000 | -11.4% | 27,300 | 0.0% | 0.02% | -5.6% | |
| VINCU | Exit | VINCERX PHARMA INCunit 12/24/2025 | $0 | – | -300,000 | -100.0% | -0.28% | – |
| ARYD | Exit | ARYA SCIENCES ACQUISTION COcl a | $0 | – | -750,000 | -100.0% | -0.35% | – |
| LABD | Exit | DIREXION SHS ETF TRdaily s&p biotec | $0 | – | -1,250,000 | -100.0% | -0.92% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| iTeos Therapeutics, Inc. | May 11, 2022 | 2,154,058 | 6.1% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
| SC 13D/A | 2024-01-25 |
| SC 13G | 2024-01-18 |
| SC 13D/A | 2023-12-18 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.